EA200801308A1 - Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик - Google Patents

Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик

Info

Publication number
EA200801308A1
EA200801308A1 EA200801308A EA200801308A EA200801308A1 EA 200801308 A1 EA200801308 A1 EA 200801308A1 EA 200801308 A EA200801308 A EA 200801308A EA 200801308 A EA200801308 A EA 200801308A EA 200801308 A1 EA200801308 A1 EA 200801308A1
Authority
EA
Eurasian Patent Office
Prior art keywords
growth factor
antimitotic
cdk inhibitor
combinations including
including cdk
Prior art date
Application number
EA200801308A
Other languages
English (en)
Other versions
EA014231B1 (ru
Inventor
Чиро Меркурио
Энрико Песенти
Марио Грация Порро
Паоло Певарелло
Original Assignee
НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. filed Critical НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.
Publication of EA200801308A1 publication Critical patent/EA200801308A1/ru
Publication of EA014231B1 publication Critical patent/EA014231B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение обеспечивает комбинацию, включающую соединение А формулы (I) или его фармацевтически приемлемую соль, и антитело, ингибирующее фактор роста, или его рецептор и/или антимитотический агент, или его производное, или пролекарство, пригодное для лечения опухолей. Химическим названием соединения А является метиламид 8-[4-(4-метилпиперазин-1-ил)фениламино]-1,4,4-триметил-4,5-дигидро-1Н-пиразоло-[4,3-h]хиназолин-3-карбоновой кислоты.
EA200801308A 2006-02-10 2007-02-02 Комбинации, включающие ингибитор cdk и антитело фактора роста или антимитотик EA014231B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06101523 2006-02-10
PCT/EP2007/051020 WO2007090794A1 (en) 2006-02-10 2007-02-02 Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic

Publications (2)

Publication Number Publication Date
EA200801308A1 true EA200801308A1 (ru) 2009-02-27
EA014231B1 EA014231B1 (ru) 2010-10-29

Family

ID=37951749

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801308A EA014231B1 (ru) 2006-02-10 2007-02-02 Комбинации, включающие ингибитор cdk и антитело фактора роста или антимитотик

Country Status (13)

Country Link
US (1) US8084027B2 (ru)
EP (1) EP1986632B1 (ru)
JP (1) JP5537035B2 (ru)
CN (1) CN101355936B (ru)
AR (1) AR059320A1 (ru)
AU (1) AU2007213791A1 (ru)
BR (1) BRPI0707580A2 (ru)
CA (1) CA2623729A1 (ru)
CL (1) CL2007000355A1 (ru)
EA (1) EA014231B1 (ru)
ES (1) ES2390237T3 (ru)
TW (1) TW200801009A (ru)
WO (1) WO2007090794A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105148B (zh) * 2008-07-24 2013-04-10 内尔维阿诺医学科学有限公司 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
JP5579715B2 (ja) * 2008-07-29 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ
CN102105151B (zh) * 2008-07-29 2013-12-18 内尔维阿诺医学科学有限公司 Cdk抑制剂在治疗神经胶质瘤中的应用
JP2012509859A (ja) * 2008-11-24 2012-04-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 中皮腫の治療のためのｃｄｋ阻害物質
CN102356083B (zh) * 2009-03-20 2014-10-15 内尔维阿诺医学科学有限公司 用于胸腺瘤治疗的激酶抑制剂的用途
JP5801285B2 (ja) * 2009-04-29 2015-10-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｃｄｋ阻害物質の塩
CN103626777B (zh) * 2009-07-29 2015-10-21 内尔维阿诺医学科学有限公司 Plk抑制剂的盐类
CN102140139B (zh) * 2010-02-03 2013-01-09 吉林大学 一种抗肿瘤人源单链抗体
RS60186B1 (sr) 2011-04-29 2020-06-30 Penn State Res Found Indukcija malog molekula trail genom u normalnim i tumorskim ćelijama kao antikancerska terapija
JP7053463B2 (ja) * 2015-11-11 2022-04-12 ナビフス コーポレーション リミテッド 超音波システムを使用して脳腫瘍を治療するための方法及びキット
JP7178401B2 (ja) * 2017-07-11 2022-11-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのピラゾロキナゾリン誘導体
WO2019090332A1 (en) * 2017-11-06 2019-05-09 Tiziana Life Sciences Plc Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
KR20200132902A (ko) * 2018-03-13 2020-11-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Egfr 활성화 돌연변이를 갖는 암의 치료 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27220A1 (es) * 2001-03-23 2002-09-30 Aventis Pharma Sa Combinación de un taxano con una quinasa ciclina-dependiente
ATE418333T1 (de) * 2002-11-06 2009-01-15 Cyclacel Ltd Kombination aus docetaxel und einem cdk-hemmer
CN1826343A (zh) * 2003-05-22 2006-08-30 法玛西雅意大利公司 吡唑并－喹唑啉衍生物、它们的制备方法和它们作为激酶抑制剂的用途
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
KR20120068807A (ko) * 2004-07-22 2012-06-27 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
EA201300320A1 (ru) * 2005-09-07 2014-02-28 Эмджен Фримонт Инк. Моноклональные антитела человека к киназе-1, подобной рецептору активина
WO2007059099A2 (en) * 2005-11-14 2007-05-24 Point Therapeutics, Inc. Boroproline combination therapy for cancer

Also Published As

Publication number Publication date
WO2007090794A1 (en) 2007-08-16
CN101355936A (zh) 2009-01-28
TW200801009A (en) 2008-01-01
EP1986632A1 (en) 2008-11-05
EA014231B1 (ru) 2010-10-29
AR059320A1 (es) 2008-03-26
CN101355936B (zh) 2013-04-24
CA2623729A1 (en) 2007-08-16
US20090017025A1 (en) 2009-01-15
ES2390237T3 (es) 2012-11-07
AU2007213791A1 (en) 2007-08-16
JP2009526009A (ja) 2009-07-16
CL2007000355A1 (es) 2008-01-18
JP5537035B2 (ja) 2014-07-02
US8084027B2 (en) 2011-12-27
EP1986632B1 (en) 2012-08-15
BRPI0707580A2 (pt) 2011-05-10

Similar Documents

Publication Publication Date Title
EA200801308A1 (ru) Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик
WO2008005956A3 (en) Pyrrolotriazine kinase inhibitors
NO20090580L (no) Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
DE60237145D1 (de) Chinazolinderivate
ATE443063T1 (de) Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
WO2006039718A3 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
ATE437872T1 (de) Proteinkinaseinhibitoren
EA200700188A1 (ru) Производные замещенного 2-алкилхиназолинона как ингибиторы parp
NO20051008L (no) Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
EA200900821A1 (ru) Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
WO2007146124A3 (en) Deuterated tadalafil derivatives
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20075113L (no) Proteinkinaseinhibitorer
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
ZA200704913B (en) 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
ATE348101T1 (de) Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion
WO2008079873A3 (en) Thiazolyl compounds useful as kinase inhibitors
IS8096A (is) Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
EA200701843A1 (ru) 2-оксо-1,2,4,5-тетрагидро-1,3-бензодиазепин-3-илпиперидины в качестве cgrp-антагонистов
PL353681A1 (en) Applications of pyrrole derivatives in production of a drug

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU